Cipla Q4 Result: Profit fell 12.4% YoY to Rs 362 crore, missed estimates

NEW DELHI: Drug Major’s consolidated net profit for the quarter ended March 12 on Tuesday fell 12.41 per cent to Rs 362.07 crore from Rs 413.38 crore in the same quarter last year.

Profit figures ET Now analyst poll estimates are significantly lower than Rs 591 crore.

Total revenue from the operation was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore in the year-ago quarter.

“I am pleased to see the continued momentum across our core market despite adverse weather conditions affecting the overall business mix. Our one-India business quarter continued its double-digit trajectory. We have crossed the $ 1 billion milestone in our domestic branded prescription business, driven by sustainable growth across our fast and long-term portfolio, ”said Umang Bhohra, MD and Global CEO, Cipla.

“Contributions from our established respiratory franchise and peptide assets have strengthened our US run rate by $ 160Mn. Adjusting for Covid Linked and other one-time charges, our core operating profitability continues to be strengthened by the strength of our business fundamentals. ”

The company said its One-India business grew 21 percent last year across branded prescription, trade generic and consumer health. The growth was a consistent 15 percent YoY increase for the Covid portfolio.

The SAGA region as a whole grew 8 percent year-over-year in USD terms; Market-beat growth in SA private continues.

U.S. businesses reported $ 160 million in revenue and 17 percent YoY growth thanks to strong traction in respiratory resources as well as contributions from peptide resources. The research and development (R&D) investment stood at Rs 322 crore or 6.1 per cent of the sales quarter, up 16 per cent year-on-year driven by the start of clinical trials on respiratory assets.